<DOC>
	<DOCNO>NCT01905046</DOCNO>
	<brief_summary>The purpose research study test whether metformin , drug commonly use treat diabetes , able get rid atypia ( early cell change think marker breast cancer risk ) woman increase risk breast cancer . There test presence atypia breast metformin give see get rid atypia . The study compare effect , good and/or bad , metformin placebo atypia find good . Note : The standard drug use `` breast cancer prevention '' tamoxifen . If patient eligible take tamoxifen , he/she must offer tamoxifen prevention part clinical care . Metformin tamoxifen similar function differently . This study investigate use tamoxifen . Metformin approve prevent breast cancer , currently test determine prevent breast cancer .</brief_summary>
	<brief_title>Metformin Hydrochloride Patients With Atypical Hyperplasia In Situ Breast Cancer Placebo Decreasing Atypical Cells Patients With Atypical Hyperplasia Situ Breast Cancer</brief_title>
	<detailed_description>A total 400 premenopausal woman ( 200 per arm ) pre-registered , among 300 patient atypia ( Masood Score 14-17 ) random periareolar fine needle aspiration ( RPFNA ) baseline expect randomized Metformin placebo control arm . It expect accrual rate 5 10 patient per month accrual complete 4 year study activation . The randomization stratify know BRCA mutation ( BRCA1 BRCA2 mutation vs. mutation ) , prior excisional biopsy ( atypical epithelial hyperplasia , atypical lobular hyperplasia , flat epithelial hyperplasia vs. DCIS vs. LCIS ) , baseline fast insulin &gt; 2x ULN vs. ≤ 2x ULN . The primary secondary objective describe . Primary Objective : • Test presence absence cytological atypia RPFNA bilateral aspirate 12 24 month ( 24 month optional placebo-only group patient remain placebo arm receive metformin ) woman receive metformin versus placebo control . The presence cytological atypia mean atypia RPFNA specimen . Secondary Objectives : - Use Masood Cytology Index Score test presence cytological atypia disappearance cytological atypia RPFNA bilateral aspirate 12 month arm , 24 month ( 24 month optional placebo-only group patient remain placebo arm receive metformin , mandatory crossover patient ) woman receive metformin 850 mg PO BID ( metformin group ) . - Compare Masood Cytology Score value 0 12 month right leave breast individual metformin placebo group . - Test reproducibility reverse phase protein microarray ( RPPM ) duplicate RPPM determination individual RPFNA specimen . - Correlate baseline RPPM value presence atypia ( measure Masood Cytology Index Score ) month 12 month 24 ( month 24 optional placebo-only group ; patient remain placebo arm receive metformin ) RPFNA . - Determine change percent breast density prior initiation metformin placebo treatment therapy ( ie , 12 24 month ) , follow therapy ( ie , 36 48 month ) . Follow visit perform 36 48 month start treatment .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Carcinoma Situ</mesh_term>
	<mesh_term>Carcinoma , Ductal , Breast</mesh_term>
	<mesh_term>Carcinoma , Intraductal , Noninfiltrating</mesh_term>
	<mesh_term>Carcinoma , Lobular</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>PreRegistration 1 . Must increase risk breast cancer , define least one follow four criterion : Having prior biopsy demonstrate atypical hyperplasia , lobular carcinoma situ ( LCIS ) , ductal carcinoma situ ( DCIS ) A Gail Model Risk ≥1.66 % 5 year A strong family history breast and/or ovarian cancer define study protocol . Known breast cancer BRCA1 BRCA2 mutation carrier provide woman : Met genetic counselor review genetic testing result , Has offer opportunity undergo prophylactic mastectomy oophorectomy 2 . Premenopausal woman define four menstrual cycle within last six month prior preregistration . Women le 4 menses within 6 month prior preregistration woman hysterectomy ovary intact consider premenopausal folliclestimulating hormone ( FSH ) level &lt; 20 . Women use hormonal contraceptive cause amenorrhea ( e.g . injectable extended oral contraceptive , hormonecontaining contraceptive ring , hormonecontaining intrauterine device ) consider eligible minimum 4 menstrual cycle within last six month prior start contraceptive . 3 . Digital mammogram within 180 day prior preregistration . 4 . Mammograms must read suspicious breast cancer ( American College Rheumatology [ ACR class IIII ) . Subjects class IV mammogram may enrol evaluate breast surgeon evidence invasive malignancy . 5 . Must nonpregnant nonlactating least one year prior preregistration . 6 . If currently menstruate , subject must use reliable method birth control . 7 . Willing provide RPFNA blood sample correlative research purpose . 8 . Women core biopsy excisional biopsy contain DCIS , LCIS atypia eligible study . 9 . Women eligible take tamoxifen must offer tamoxifen prevention part clinical care refuse tamoxifen treatment . Preregistration 1 . Other active malignancy ≤ 5 year prior preregistration . EXCEPTIONS : Nonmelanotic skin cancer carcinomainsitu cervix . NOTE : If history prior malignancy , must receive specific treatment , i.e. , hormonal therapy , cancer . 2 . Body mass index ( BMI ) &lt; 25 . 3 . Receiving warfarin . 4 . Bilateral breast implant autologous breast flap reconstruction . 5 . Active diagnosis alcoholism . 6 . Contraindication metformin prevention acute hypersensitivity allergic reaction metformin . 7 . Receiving tamoxifen raloxifene . 8 . Administration investigational agent ≤ 30 day prior preregistration . 9 . Previous radiation breast . 10 . Comorbid systemic illness severe concurrent disease , judgment investigator , would make patient inappropriate entry study interfere significantly proper assessment safety toxicity prescribe regimen . 11 . Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . 12 . Receiving pyrimethamine , cimetidine , rifampin cephalexin . 13 . Women core biopsy excisional biopsy contain invasive cancer . 14 . Women take metformin within past 90 day . 15 . Patients hemoglobin alc &gt; 6.3 actively treat diabetes . Registration/Randomization 1 . Qualifying cytological atypia RPFNA , Masood score 1417 . 2 . Required laboratory value obtain 30 day prior registration/randomization . 1 . Hemoglobin ≥ 9 g/dL . 2 . Absolute neutrophil count ( ANC ) ≥ 1500/mm^3 . 3 . Platelet count ≥ 75,000/mm^3 . 4 . Creatinine ≤ 1.4 mg/dL 5 . Total bilirubin ≤ 3.0 mg/dL . 6 . Aspartate trasaminase ( AST ) ≤ 3 x upper limit normal ( ULN ) . 7 . Alanine transaminase ( ALT ) ≤ 3 x ULN . 3 . Negative pregnancy test do ≤ 7 day prior registration/randomization , woman childbearing potential . A female childbearing potential sexually mature female : 1 ) undergone hysterectomy bilateral oophorectomy 2 ) naturally postmenopausal least 12 consecutive month ( ie , menses time precede 12 consectuve imonths ) .</criteria>
	<gender>Female</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>